CN111787921A - 锌离子载体及其用途 - Google Patents

锌离子载体及其用途 Download PDF

Info

Publication number
CN111787921A
CN111787921A CN201880076537.2A CN201880076537A CN111787921A CN 111787921 A CN111787921 A CN 111787921A CN 201880076537 A CN201880076537 A CN 201880076537A CN 111787921 A CN111787921 A CN 111787921A
Authority
CN
China
Prior art keywords
zinc
pharmaceutically acceptable
optionally substituted
antibiotic
ionophore
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880076537.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·沃克尔
C·麦科德维特
M·范艾特兹特恩
A·麦克万
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Griffith University
Adelaide University
Original Assignee
University of Adelaide
University of Queensland UQ
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904135A external-priority patent/AU2017904135A0/en
Application filed by University of Adelaide, University of Queensland UQ, Griffith University filed Critical University of Adelaide
Publication of CN111787921A publication Critical patent/CN111787921A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880076537.2A 2017-10-13 2018-10-12 锌离子载体及其用途 Pending CN111787921A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904135A AU2017904135A0 (en) 2017-10-13 Compositions and their uses
AU2017904135 2017-10-13
PCT/AU2018/051116 WO2019071325A1 (en) 2017-10-13 2018-10-12 ZINC IONOPHORES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN111787921A true CN111787921A (zh) 2020-10-16

Family

ID=66100161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076537.2A Pending CN111787921A (zh) 2017-10-13 2018-10-12 锌离子载体及其用途

Country Status (6)

Country Link
US (1) US20200261440A1 (https=)
EP (1) EP3694515A4 (https=)
JP (2) JP7514763B2 (https=)
CN (1) CN111787921A (https=)
AU (1) AU2018348796B2 (https=)
WO (1) WO2019071325A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165050A1 (zh) * 2022-03-04 2023-09-07 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3114742B1 (fr) * 2020-10-04 2026-01-02 Bruno Eto Composition pharmaceutique ou diététique pour bloquer la synthèse des peptides par les ribosomes.
FI4426434T3 (fi) 2021-11-02 2025-11-24 Flare Therapeutics Inc Pparg:n käänteisagonisteja ja niiden käyttöjä
WO2024026525A1 (en) * 2022-08-01 2024-02-08 Griffith University Antibacterial compound pbt2
CN120695002A (zh) * 2025-06-24 2025-09-26 南方医科大学南方医院 Pbt2在制备抗白念珠菌生物膜药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8－羟基喹啉衍生物
WO2009140215A2 (en) * 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
WO2017053696A2 (en) * 2015-09-24 2017-03-30 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696083A (en) * 1992-11-10 1997-12-09 Olin Corporation Personal care composition containing pyrithione and polymyxin
KR101329587B1 (ko) * 2005-06-28 2013-11-15 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
US20110189260A1 (en) * 2008-05-30 2011-08-04 University Of Cincinnati Use of zinc chelators to inhibit biofilm formation
US9821063B2 (en) * 2013-04-16 2017-11-21 University Of Cincinnati Antimicrobial compositions of aminoglycosidic antibiotics and zinc ion chelators specifically formulated for enhanced inhibition of bacterial colonization and antibacterial efficacy
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
US20180168157A1 (en) * 2015-06-23 2018-06-21 Janssen Pharmaceutica Nv Antimicrobial compositions comprising food approved antimicrobials and zinc pyrithione

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8－羟基喹啉衍生物
WO2009140215A2 (en) * 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
WO2017053696A2 (en) * 2015-09-24 2017-03-30 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CATLYN BLANCHARD ETAL.: "Zinc Pyrithione Improves the Antibacterial Activity of Silver Sulfadiazine Ointment", 《AMERICAN SOCIETY FOR MICROBIOLOGY》 *
KEVIN CHIEM ETAL.: "Inhibition of Aminoglycoside 6=-N-Acetyltransferase Type Ib-Mediated Amikacin Resistance in Klebsiella pneumoniae by Zinc and Copper Pyrithione", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
MICHEL NGUYEN ETAL.: "Structures of copper- and zinc-complexes of PBT2, chelating agent evaluated as potential drug for neurodegenerative diseases", 《EUROPEAN JOURNAL OF INORGANIC CHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165050A1 (zh) * 2022-03-04 2023-09-07 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物

Also Published As

Publication number Publication date
JP2020536966A (ja) 2020-12-17
EP3694515A4 (en) 2021-04-21
WO2019071325A1 (en) 2019-04-18
JP2024073569A (ja) 2024-05-29
US20200261440A1 (en) 2020-08-20
AU2018348796B2 (en) 2024-09-26
AU2018348796A1 (en) 2020-05-07
JP7514763B2 (ja) 2024-07-11
EP3694515A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
JP2024073569A (ja) 亜鉛イオノフォアおよびその使用
JP5665756B2 (ja) 抗細菌化合物
EP3578548A1 (en) Antibiotic tolerance inhibitors
JP6150841B2 (ja) クロストリジウム・ディフィシル関連疾患を治療するための化合物
JP2002505689A (ja) キノリン−インドール抗菌剤、それらに関する用途及び組成物
CN108368079A (zh) 治疗细菌感染的化合物及方法
WO2018177218A1 (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
JP2011528354A (ja) 抗生物質
CN117098540A (zh) 与万古霉素联合的利福霉素类似物及其用途
US11040949B2 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
JP6590924B2 (ja) 微生物感染を治療するための相乗的組成物
WO2011151619A1 (en) Compounds for the treatment of clostridium difficile associated disease
US10941114B2 (en) Small molecule lipid II inhibitors
CN107406409B (zh) 泛酸酰胺类似物
US20200147086A1 (en) Inhibitors of nucleotidyltransferase superfamily enzymes as antibiotics
US10961214B2 (en) Small molecule lipid II inhibitors
US20230278971A1 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
US20250228841A1 (en) Compositions affecting pigment production and methods for treatment of bacterial diseases
WO2013066469A2 (en) Kinase inhibitors capable of increasing the sensitivity of bacterial pathogens to b-lactam antibiotics
US20210309622A1 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
CA2534957A1 (en) Antibiotic cycloalkyltetrahydroquinoline derivatives
Bhawsar et al. WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections
JENA et al. Synthesis, Biological Evaluation, Molecular Modeling, and Docking Studies of Ciprofloxacin Derivatives
FR2941956A1 (fr) NOUVELLES MOLECULES HYBRIDES VANCOMYCINE-AMINOQUINOLEINE DENOMMEES "VANCOMYQUINESr", LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2011151617A1 (en) Compounds for the treatment of clostridium difficile associated disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination